Case Report

Progressive Intramuscular Haematoma in a 12-Year-Old Boy: A Case of Acquired Haemophilia A

Manori Gamage,1 Sadeepa Weerasinghe,2 Mohamed Nasoor,2 A. M. P. W. Karunarathne,3 and Sashi Praba Abeyrathne3

1Senior Lecturer, Department of Paediatrics, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
2Paediatric Registrar, University Paediatric Unit, Colombo South Teaching Hospital Kalubowila, Dehiwala-Mount Lavinia, Sri Lanka
3Senior Registrar, Department of Pathology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka

Correspondence should be addressed to Manori Gamage; manorigamage@sjp.ac.lk

Received 22 June 2018; Accepted 8 October 2018; Published 24 October 2018

Acquired hemophilia A (AHA) is a rare bleeding disorder due to acquired antibodies against coagulation factor VIII (FVIII). It is rare in children less than 16 years old, and the incidence is 0.45/million/year. Although AHA is associated with autoimmune disorders, infections, malignancies, drugs, and pregnancy, no cause was identified in 50% of cases [3].

Here, we report a case of an acquired haemophilia A in a previously healthy 12-year-old boy.

1. Introduction

Acquired haemophilia A (AHA) is a rare bleeding disorder. It occurs due to acquired antibodies against coagulation factor VIII (FVIII). Generally, it has an incidence rate of 1 to 4 per million/year with a biphasic distribution pattern which demonstrates a small peak in young individuals aged between 20 and 30 years and major peak in individuals around 60–80 years [1]. It is rarer in children less than 16 years, and the incidence is 0.45/million/year [2]. Although this is a rare disorder, it is associated with significant morbidity and mortality.

Although AHA is associated with autoimmune disorders, infections, malignancies, drugs, and pregnancy, no cause was identified in 50% of cases [3].

Here, we report a case of an acquired haemophilia A in a previously healthy 12-year-old boy.

2. Case Report

Otherwise healthy, 12-year-old boy was admitted to the ward with a history of swelling of the right and left forearms, for 1 day duration.
He gave a history of a swelling in the right forearm first noticed six weeks prior to the current presentation, and it has resolved gradually without any acute intervention. During the initial presentation, the mother claimed that he was treated with a course of amoxycillin for an upper respiratory tract infection prior to the onset of the swelling. Since then, he was well till this current admission.

During this presentation, the swelling of the right elbow joint along with the forearm swelling worsened progressively. He did not have any history of trauma or febrile illness associated with the current presentation.

He denied any bleeding tendency in the past except a history of mild extra bleeding which settled spontaneously following a dental extraction one month back. There was no history of photosensitive skin rashes, renal problems, recent weight loss, or poor appetite. He did not have any family history of bleeding disorders.

On examination, he was alert, pale but not icteric or febrile. His weight:height ratio lied between 1 SD and median. He did not have lymphadenopathy, hepatosplenomegaly, or ballotable masses.

Examination of the upper limbs revealed that the range of movements was reduced due to the pain and there was diffused tense swelling of both forearms. But there were no inflammatory changes noted on the over line skin or adjacent joints of the swollen areas. Rest of his systemic examination was unremarkable.

During initial investigations, his full blood count revealed a white cell count of $8.62 \times 10^9$ with a normal differential count. His haemoglobin was $7.7 \text{g/dl}$ with a platelet count of $278 \times 10^9$/L.

His clotting profile showed a normal PT/INR with normal bleeding and clotting time but his APPT was significantly prolonged (patient: 109.9 seconds; control: normal). His factor assay showed that factor VIII level was significantly prolonged (patient: 109.9 seconds; control: normal bleeding and clotting time but his APPT was significantly prolonged).

Antinuclear and antiphospholipid antibodies were negative.

Intracranial bleeding [3]. AHA is associated with a high mortality rate of more than 20% which is due to either retroperitoneal or intracranial bleeding [3].

Diagnosis of AHA should be suspected in patients present with acute onset of significant bleeding manifestations without a previous history of bleeding disorder [3]. The diagnosis can be confirmed by isolated prolongation of activated partial thromboplastin time (aPTT), which does not normalize after addition of normal plasma and incubation for one two hours, reducing the factor VIII levels with evidence of FVIII inhibitor activity. They have normal prothrombin time and platelet functions [6]. The FVIII inhibitor level is measured by the Bethesda assay and expressed as Bethesda units (BU) [3] (Figure 1).

Management of AHA involves two aspects, namely; eradication of antibodies and maintaining effective haemostasis during a bleeding episode [1, 7].

The options used to control an acute bleed are based on the level of antibody titer [1]. If the patient’s antibody titer is low (<5 BU), it can be managed with human factor VIII concentration + DDAVP administration [1, 7]. If the patient’s antibody titer is high (>5% BU), it is managed with bypassing agents. They include recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) with an efficacy of 95% and 86% respectively [1].
Our patient was initially treated with aPCC with a poor response, and acute bleeding was controlled with recombinant activated factor VII. Patients with AHA should be immediately started on immunosuppressive therapy on diagnosis to eradicate FVIII inhibitors [2,3]. Most frequently used therapeutic agents are corticosteroids: prednisolone (1 mg/kg/day for 3 weeks) as a single agent or in combination with cyclophosphamide (2 mg/kg/day) [2, 3]. A meta-analysis has concluded that cyclophosphamide was superior to prednisolone to eradicate inhibitors but not in overall survival [1]. Our patient was commenced on prednisolone 1 mg/kg/day to eradicate inhibitors.

There is necessary evidence on the effectiveness of other treatment approaches such as immune tolerance regimens and rituximab, when first-line immunosuppressive therapy fails or is contraindicated. But there is conflicting evidence in relation to high dose immunoglobulin therapy [1, 3].

Complete inhibitor eradication is defined as undetectable inhibitor and normal FVIII levels. Patients who are on immunosuppressive therapy need regular follow-up as an out-patient basis for a minimum period of 2 years. Their assessment should include physical examination, full blood count, aPTT, and FVIII inhibitor titer assay [3].

Though AHA is a rare entity, especially in children, it should not be missed in differential diagnosis, provided the clinical presentation is suggestive.

**Consent**

Written informed consent was obtained from both parents.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

The authors thank Dr. Indira Wijesiriwardena, Dr. Bernadine Fernandupulle, Dr. Chandima Kulathilake, and Dr. Chamariya Munasinghe, Consultant Haematologists from the Department of Pathology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

**References**

[1] I. Elezovic, “Acquired haemophilia syndrome: pathophysiology and therapy,” Srpski Arhiv za Celokupno Lekarstvo, vol. 138, no. 1, pp. 64–68, 2010.

[2] M. Franchini and P. M. Mannucci, “Acquired haemophilia A: a 2013 update,” Thrombosis and Haemostasis, vol. 110, no. 12, pp. 1114–1120, 2013.

[3] A. Huth-Kuhne, F. Baudo, P. Collins et al., “International recommendations on the diagnosis and treatment of patients with acquired hemophilia A,” Haematologica, vol. 94, no. 4, pp. 566–575, 2009.

[4] O. E. L. Graoui, S. Faez, and B. Oukkahe, “A case of acquired haemophilia A with maxillary osteitis,” Macedonian Journal of Medical Sciences, vol. 5, no. 4, pp. 434–436, 2012.

[5] M. Franchini, G. Gandini, T. Di Paolantonio, and G. Mariani, “Acquired Haemophilia A: a concise review,” American Journal of Hematology, vol. 80, no. 1, pp. 55–63, 2005.

[6] M. Franchini and G. Lippi, “Acquired factor VIII inhibitors,” Blood, vol. 112, no. 2, pp. 250–255, 2008.

[7] S. Shetty, M. Bhave, and K. Ghosh, “Acquired haemophilia A: diagnosis, aetiology, clinical spectrum and treatment options,” Autoimmunity Reviews, vol. 10, no. 6, pp. 311–316, 2011.